CBER head Peter Marks weighs in on cell, gene therapy pricing debateBioWorld OnlineDUBLIN – Last week Philadelphia-based Spark Therapeutics Inc. reported $2.4 million revenue for the debut quarter of Luxturna (voretigene neparvovec-rzyl), its gene ther… Continue reading
The Denver ChannelStem cell therapies: Beware of unproven treatments and wild marketing claimsThe Denver ChannelDENVER – When Eduardo Dominguez found himself dealing with crippling hip pain, he went to a surgeon who told him he needed to have his entir… Continue reading
Edgy Labs (blog)Beam Therapeutics Opens with $87-million for CRISPR InnovationsEdgy Labs (blog)CRISPR-Cas9 is the strep-bacteria-derived gene-editing biotech sweeping the scientific world. We have written about it on many occasions, so feel free to re-… Continue reading
XconomyStem Cell Maker StemBioSys Closes $4.3M Financing for New ProductsXconomyThe company took its focus off of fundraising in 2017 to launch new branding for its lead product, an extracellular matrix used to replicate stem cells now called CELLvo Ma… Continue reading
Managing Adverse Effects of Immunotherapy in Genitourinary Cancerswww.oncnursingnews.com/Adverse effects (AEs) typically require a multidisciplinary approach among health care teams. Guidelines from organizations such as ASCO, NCCN, and ESMO have been … Continue reading
Fortune |
Brainstorm Health: All Payer in Maryland, California STD Cases, New CRISPR Company
Fortune Good afternoon, readers. This is Sy. First things first—I’d like to apologize for a snafu with our newsletter yesterday. Due to a technical problem, the news blurbs that usually accompany our essays didn’t show up in Monday’s email. The issue’s been … |